Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 21:21:55 Source:worldViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Amal Clooney played key role in ICC bid to request arrest warrants for Israeli PM and Hamas leader
You may also like
- Uber and Lyft say they'll stay in Minnesota after Legislature passes driver pay compromise
- EU, G7 leaders urge preventing escalation in Mideast
- Trump goes from court to campaign at a NYC bodega
- Ryan Weathers strikes out a career
- Jude Bellingham's new model girlfriend Laura Celia Valk looks sensational in a figure
- Trump to meet with Polish president Duda as NATO leaders call for additional support for Ukraine
- Barry Keoghan sports a Burberry bandana on his face as he playfully poses with Stormzy at Coachella
- Mental health review to follow Sydney stabbing attack: Australian PM
- Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky